AVE7688 dose-ranging study versus losartan in mild to moderate essential hypertension

Phase 2, randomised, double-blind trial of ilepatril in essential hypertension (5 arms), sponsored by Sanofi. Primary endpoints: Change from baseline in trough seated diastolic blood pressure at week 12 and Change from baseline in trough seated systolic blood pressure at week 12. Started Oct 2005; status: completed.